Lifecore Biomedical, Inc. De (LFCR) Cash & Equivalents (2010 - 2025)

Lifecore Biomedical's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $8.3 million for Q2 2025.

• In Q2 2025, Cash & Equivalents fell 2.33% year-over-year to $8.3 million; the TTM figure through May 2025 stood at $8.3 million (down 2.33% YoY), while the FY2025 annual figure was $8.3 million, down 2.33% from the prior year.
• Cash & Equivalents was $8.3 million for Q2 2025 at Lifecore Biomedical, up from $5.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $19.1 million in Q2 2023 to a low of $609000.0 in Q4 2021.
• Historically, Cash & Equivalents has averaged $4.9 million across 5 years, with a median of $2.7 million in 2022.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents tumbled 75.4% in 2021, then soared 1826.44% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $609000.0 in 2021, then surged by 875.04% to $5.9 million in 2022, then soared by 221.51% to $19.1 million in 2023, then slumped by 50.47% to $9.5 million in 2024, then decreased by 12.59% to $8.3 million in 2025.
• The last three Cash & Equivalents figures came in at $8.3 million (Q2 2025), $5.4 million (Q1 2025), and $9.5 million (Q4 2024), per Business Quant data.